Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes -

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Diabetes
Summary
In RCT (n=3297 on standard regimen), primary outcome [PO] (1st occurrence CV death, nonfatal MI or stroke) occurred in 108 of 1648 (6.6%) on once-weekly semaglutide (0.5/1.0 mg) and 146 of 1649 (8.9%) on placebo (HR, 0.74; 95% CI, 0.58- 0.95; p<0.001; noninferiority for PO).
UKMi comment
Semaglutide is a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week. According to a Reuters report, Novo intends to file for regulatory approval of semaglutide in the US and Europe in the last quarter of 2016.
Related links: Reuters report